Jones Financial Companies Lllp Raises Position in Bristol Myers Squibb Company $BMY

Jones Financial Companies Lllp increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,464 shares of the biopharmaceutical company’s stock after buying an additional 15,554 shares during the quarter. Jones Financial Companies Lllp’s holdings in Bristol Myers Squibb were worth $10,482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CVA Family Office LLC raised its position in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 223 shares during the last quarter. Mccarter Private Wealth Services LLC raised its holdings in shares of Bristol Myers Squibb by 5.0% in the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 235 shares during the last quarter. Creative Financial Designs Inc. ADV lifted its stake in shares of Bristol Myers Squibb by 26.7% during the second quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 237 shares during the period. Center for Financial Planning Inc. grew its holdings in shares of Bristol Myers Squibb by 15.9% during the second quarter. Center for Financial Planning Inc. now owns 1,869 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 256 shares during the last quarter. Finally, Tilson Financial Group Inc. grew its holdings in shares of Bristol Myers Squibb by 4.2% during the third quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 259 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Wells Fargo & Company upped their price objective on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Finally, Morgan Stanley reissued an “underweight” rating and set a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $57.43.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $57.70 on Thursday. The company has a market capitalization of $117.46 billion, a PE ratio of 19.49, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The company’s fifty day moving average price is $53.88 and its 200 day moving average price is $48.85. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 85.14%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.